| Old Articles: <Older 5501-5510 Newer> |
 |
The Motley Fool March 17, 2009 Brian Orelli |
Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace.  |
The Motley Fool March 16, 2009 Brian Orelli |
Will the New FDA Chief Make Your Investments Healthy? President Obama's choice of Margaret Hamburg as head of the FDA seems to signify that the president is interested in the agency turning its focus toward protecting American's health.  |
Chemistry World March 13, 2009 Sarah Houlton |
Mega mergers sweep pharma industry Just six weeks after Pfizer agreed to buy Wyeth, US pharma companies Merck & Co. and Schering-Plough announced they are to merge.  |
The Motley Fool March 13, 2009 Brian Orelli |
Will These Drugs Get Past the FDA? Let's take a look at which pharma companies are hoping to score with the FDA this month.  |
The Motley Fool March 13, 2009 Brian Orelli |
Pfizer Finally Gets a Hit! Positive results on Pfizer's cancer drug Sutent come earlier than expected.  |
The Motley Fool March 12, 2009 Brian Orelli |
2 Suitors Are Better Than 1 Recent drug company acquisitions prove that competition benefits shareholders.  |
The Motley Fool March 12, 2009 Robert Steyer |
A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another.  |
Pharmaceutical Executive March 1, 2009 Porth & Sillup |
Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it.  |
Pharmaceutical Executive March 1, 2009 Brittany Agro |
The New Sales Force The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with, and how it's working.  |
Pharmaceutical Executive March 1, 2009 Brittany Agro |
Ad Stars 2009 Twelve agencies behind some of industry's most captivating work.  |
| <Older 5501-5510 Newer> Return to current articles. |